Genocea Biosciences Announces Collaboration to Characterize T Cell Responses to Cancer Antigens

March 3, 2014 Genocea Biosciences, Inc., a company pioneering novel T cell vaccines and immunotherapies, today announced a joint research collaboration with Dana-Farber Cancer Institute and Harvard Medical School to characterize anti-tumor T cell responses in melanoma patients. This collaboration extends the use of the company’s proprietary ATLAS™ platform for the rapid discovery of T cell antigens to cancer immunotherapy approaches. “ATLAS™ has proven …